September 25, 2025Scientific ReportsOpen Access

MCC950 targets the ROS-NEK7-NLRP3 axis to improve type 2 diabetic retinopathy

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Research reveals MCC950 improves retinal health in diabetic rats by inhibiting NLRP3 inflammasome activation, suggesting potential for new therapies.

MCC950 markedly improves retinal histopathological alterations in type 2 diabetic male rats, and its peak efficacy occurs at a concentration of 1 mM.
Quantitative assessments show significant modulation of retinal apoptosis and oxidative stress, particularly at 1 mM concentration of MCC950.
Analysis indicates MCC950 disrupts NEK7-NLRP3 interaction, reducing NLRP3 inflammasome activation and pathway-associated protein expression.
Findings support a mechanistic role for MCC950 in alleviating oxidative stress and retinal inflammation, highlighting therapeutic potential.

Ren et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Research reveals MCC950 improves retinal health in diabetic rats by inhibiting NLRP3 inflammasome activation, suggesting potential for new therapies.